Acquired by New Relic.
THERAtRAME develops and positions new therapeutics targeting tRNA epitranscriptomics in cancer.
Trince developed a new transfection technology based on a combination of laser light and photothermal nanoparticles.
EyeD Pharma is developing micro-implants for drug release over a prolonged period of time.
